摘要基于子宫颈癌筛查现状以及筛查方法、策略的发展，中国中西医结合学会检验医学专业委员会联合4个学（协）会，组织检验、病理、妇产多学科专家共同制定了甲基化检测与临床应用的共识。共识全面梳理了PAX1联合JAM3双基因甲基化（PAX1 m/JAM3 m）检测的实验室操作流程及质控标准、样本采集与处理，提出了PAX1 m/JAM3 m检测意义及功能、实验室检测流程、质量控制、检测报告及临床应用建议。共识旨在推动子宫颈癌甲基化在实验室检测与临床的规范化应用，为检测结果的准确性和可靠性，并为明确临床应用场景，提供具备实践性与前瞻性的指导。

abstractsBased on the current status of cervical cancer screening and the development of screening methods and strategies, Laboratory Medicine Committee of Chinese Association of Integrative Medicine collaborated with four academic (or professional) societies, involving multidisciplinary experts in laboratory testing, pathology, and obstetrics and gynecology, jointly formulated this expert consensus recommendations for methylation testing and clinical application of PAX1 and JAM3 for cervical cancer. This expert consensus thoroughly outlines the laboratory operational procedures and quality control standards for the PAX1 combined with JAM3 dual-gene methylation (PAX1 m/JAM3 m) testing, as well as specimen collection and handling. It discusses the significance and functionality of PAX1 m/JAM3 m testing, the laboratory testing process, quality control, testing reports, and provides detailed clinical application suggestions. The aim of this expert consensus is to promote the standardized application of cervical cancer methylation testing in laboratories and clinical settings, ensuring the accuracy and reliability of test results, clarifying clinical application scenarios, and providing practical and forward-looking guidance.